Interestingly, a VEGF and VEGFR genotyping analysis in tumor and blood samples of 138 regorafenib-treated mCRC patients showed that a single nucleotide polymorphism in VEGF-A had an independent association with progression-free and overall survival [59]. Here, VEGFA is linked to neoplasm.